Mij
Senior Member (Voting Rights)
Key points
Historically, MCAS like other complex chronic complex disorders, has at times been mischaracterized as a psychogenic disorder. Advances in immunology and neurobiology have since provided a clearer biologic understanding of the bidirectional cross talk between mast cells and the peripheral nervous system. Despite progress in mast cell biology and the development of emerging diagnostic and therapeutic approaches, the heterogeneous presentation of MCAS and its overlap with autonomic dysfunction . . .
Clinical care points
-Symptom Monitoring: Key indicators include flushing, urticaria, angioedema, abdominal cramping, diarrhea, hypotension, tachycardia, and “brain fog.”
-Laboratory Timing: Objective evidence of activation is best obtained by measuring serum tryptase within four hours of an acute episode. A significant increase is defined as 20% over baseline plus 2 ng/mL.
-Mediator Testing: Beyond tryptase, clinical evaluation may include urinary metabolites such as N-methyl histamine, prostaglandin D2 or F2alpha, or . . .
Link
- •
MCAS is defined by the presence of mast cell activation symptoms, elevated biomarkers and response to H1-antihistamines or mast-cell stabilizing agents. - •
MCAS shares significant symptom overlap with mimickers such as postural orthostatic tachycardia syndrome, hereditary alpha tryptasemia, and systemic mastocytosis. - •
Due to the ubiquitous nature of mast cell and the bidirectional neuroimmune cross talk, patients with MCAS exhibit multisystemic manifestations. - •
MCAS patients require comprehensive, . . .
Historically, MCAS like other complex chronic complex disorders, has at times been mischaracterized as a psychogenic disorder. Advances in immunology and neurobiology have since provided a clearer biologic understanding of the bidirectional cross talk between mast cells and the peripheral nervous system. Despite progress in mast cell biology and the development of emerging diagnostic and therapeutic approaches, the heterogeneous presentation of MCAS and its overlap with autonomic dysfunction . . .
Clinical care points
-Symptom Monitoring: Key indicators include flushing, urticaria, angioedema, abdominal cramping, diarrhea, hypotension, tachycardia, and “brain fog.”
-Laboratory Timing: Objective evidence of activation is best obtained by measuring serum tryptase within four hours of an acute episode. A significant increase is defined as 20% over baseline plus 2 ng/mL.
-Mediator Testing: Beyond tryptase, clinical evaluation may include urinary metabolites such as N-methyl histamine, prostaglandin D2 or F2alpha, or . . .
Link